SLP (Simulations Plus) ROCE %: 17.22% (As of Feb. 2026)


SLP Simulations Plus Inc SLP
81 GF Score
Price $18.38
GF Value $38.31
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Simulations Plus ROCE %?

Simulations Plus SLP +0.22% 81 ROCE % is 17.22% as of Feb. 2026. GuruFocus rates SLP with a GF Score™ of 81/100 and a GF Value™ of $38.31 (Significantly Undervalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Simulations Plus's annualized ROCE % for the quarter that ended in Feb. 2026 was 17.22%.

Simulations Plus  (NAS:SLP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Simulations Plus ROCE % Related Terms

Simulations Plus ROCE % Historical Data

* Premium members only.

The historical data trend for Simulations Plus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simulations Plus ROCE % Chart

Simulations Plus Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.70 8.54 5.20 3.42 4.19

Simulations Plus Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.74 7.61 2.11 2.26 17.22
SLP
81GF Score
Simulations Plus Inc SLP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simulations Plus ROCE % Calculation

Simulations Plus's annualized ROCE % for the fiscal year that ended in Aug. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=6.492/( ( (196.639 - 12.069) + (131.936 - 6.725) )/ 2 )
=6.492/( (184.57+125.211)/ 2 )
=6.492/154.8905
=4.19 %

Simulations Plus's ROCE % of for the quarter that ended in Feb. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Feb. 2026 )  (Q: Nov. 2025 )(Q: Feb. 2026 )
=22.52/( ( (137.831 - 10.34) + (146.484 - 12.343) )/ 2 )
=22.52/( ( 127.491 + 134.141 )/ 2 )
=22.52/130.816
=17.22 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 17.22% mean?
Simulations Plus (SLP) has a ROCE % of 17.22% as of Feb. 2026.
Is Simulations Plus' ROCE % too high?
Simulations Plus' current ROCE % is 17.22%. The Healthcare Providers & Services industry median ROCE % is 6.41. Simulations Plus' value of 17.22% is 168.6% above this industry median. Overall, Simulations Plus has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' ROCE % compare to TBRG and CARL?
Simulations Plus' ROCE % of 17.22% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Simulations Plus' value of 17.22% is 168.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 643 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current ROCE % of 17.22% is 168.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current ROCE % is 17.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (SLP) is currently considered Significantly Undervalued. The stock's GF Value™ is $38.31, compared to a current price of $18.38 — trading 52% below its estimated fair value. The current ROCE % is 17.22% and 168.6% above the Healthcare Providers & Services industry median of 6.41. Simulations Plus' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Simulations Plus (SLP), the current ROCE % is 17.22% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simulations Plus (SLP) Overvalued in 2026?

Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued. The current stock price of $18.38 is trading 52% below its estimated GF Value™ of $38.31. GuruFocus considers Simulations Plus to be Significantly Undervalued.

Key valuation signals for SLP:

  • ROCE %: 17.22%
  • GF Value™: $38.31 vs. price of $18.38 (52% below fair value)
  • GF Score™: 81/100 with 7 warning signs
  • Industry Position: 168.6% above the Healthcare Providers & Services median

No single metric tells the full story. See the SLP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simulations Plus Business Description

Other Exchanges SD3:Germany
Address 800 Park Offices Drive, Suite 401, Research Triangle Park, Lancaster, NC, USA, 27709
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
81GF Score

Get the complete analysis for SLP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.38
Price
$38.31
GF Value